Observational studyTranslational vision science & technology2025
Plasma Protein Mediation of the Association Between Blood Pressure and Retinal Vascular Occlusion.
Observational study in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the associations of hypertension history, blood pressure (BP) levels, and parameters with retinal vascular occlusion (RVAO) risk, and to identify potential mediating plasma proteins. Methods: The cohort study used data from 439,057 UK Biobank participants. Multivariable Cox regression was used to evaluate associations between incident RVAO and exposures: hypertension history (with stratification of control status and disease duration), hypertension stages (per 2017 guidelines), systolic BP (SBP), diastolic BP (DBP), mean arterial BP (MABP), and pulse pressure (PP). Mendelian randomization (MR) was subsequently used to assess causality and identify mediating plasma proteins. Results: In observational analysis, hypertension history (uncontrolled and long/unknow duration), stage 1 hypertension, stage 2 hypertension, higher BP parameters (SBP, MABP, and PP) were associated with an increased risk of RVAO, whereas DBP showed no significant association. The MR analysis supported the causal relationships for hypertension history and SBP but not for DBP. Six plasma proteins were identified as potential mediators for the hypertension history, with secretory leukocyte peptidase inhibitor (SLPI) explaining the largest proportion of the effect (13.3%). Ankyrin Repeat and SOCS Box Containing 9 (ASB9) was found to mediate the effects for both hypertension history (3.56%) and SBP (4.31%) to RVAO. Conclusions: Hypertension history and elevated SBP were significant risk factors for RVAO. Specific plasma proteins, notably SLPI and ASB9, may serve as mediators and represent potential targets for therapeutic intervention. Translational Relevance: The identification of mediating plasma proteins, such as SLPI and ASB9, provides novel therapeutic targets and biomarkers for preventing RVAO among individuals with hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.